BUB1 inhibitor BAY1816032 increases radiosensitization by cisplatin (BAY1816032 + cisplatin + IR; Figure 6D–F), paclitaxel (BAY1816032 + paclitaxel + IR; Figure 6G–I), and olaparib (BAY1816032 + olaparib + IR; Figure 6J–L) in NSCLC (A549, H2030 and H1975) cell lines. The gene discussed is BUB1; the disease is non-small cell lung carcinoma.